Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Qiagen ( (QGEN) ).
Qiagen N.V. has released its quarterly report for the period ended June 30, 2025, prepared under U.S. GAAP. The report highlights financial performance, including an increase in total assets to $5.82 billion from $5.69 billion at the end of 2024, and a rise in goodwill and intangible assets. These financial results reflect Qiagen’s ongoing efforts to strengthen its market position and operational capabilities, which could have positive implications for stakeholders and the company’s competitive standing in the biotechnology sector.
The most recent analyst rating on (QGEN) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
Spark’s Take on QGEN Stock
According to Spark, TipRanks’ AI Analyst, QGEN is a Outperform.
Qiagen’s overall stock score is driven by strong earnings call performance and positive technical indicators. Financial stability and operational efficiency support the score, though high valuation and regional sales challenges are noted.
To see Spark’s full report on QGEN stock, click here.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, specializing in sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company focuses on providing solutions for the extraction, purification, and analysis of DNA, RNA, and proteins.
Average Trading Volume: 1,456,699
Technical Sentiment Signal: Buy
Current Market Cap: $10.65B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.